XenoPort, Inc. Provides Highlights Of HORIZANT Prescription Trends And Update On Development For Alcohol Use Disorder

SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort (NASDAQ:XNPT) today reported an update on prescription trends and further development of HORIZANT® (gabapentin enacarbil) Extended-Release Tablets, including feedback from the U.S. Food and Drug Administration (FDA) on development for treatment of alcohol use disorder (AUD).

Help employers find you! Check out all the jobs and post your resume.